Navigation Links
Study shows different approach after progression in non-small cell lung cancer patients
Date:11/15/2012

DENVER Right now, the best known treatment for patients with metastatic non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase gene rearrangements (ALK) or epidermal growth factor receptor mutations (EGFR) is crizotinib or EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib, respectively. However, progression inevitably occurs. When it does, having no clear guidelines and/or indications, most patients are treated with chemotherapy. A new study published in the December 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, shows that other approaches to overcome acquired resistance should be considered.

Researchers looked at NSCLC patients with histologically confirmed ALK rearrangements or EGFR mutations who were treated with crizotinib or erlotinib at the University of Colorado Cancer Center between May 2005 and December 2011.

Of the 51 patients whose cancer grew eventually on the targeted drugs, 25 were deemed suitable for local ablative therapy radiotherapy or surgery) to the site of progression, and then continued on the same drug. The use of this strategy prolonged the duration of disease control by the drug by 6.2 months, on top of the median of 9.8 months initial disease control. The benefit was most marked in patients who only experienced isolated growth in the brain this group had another median 7.1 months of disease control before further growth either in the body and brain.

While the authors point out study limitations and the need for further research, they say their experience suggests that when NSCLC patients with EGFR mutations or ALK rearrangements "progress on erlotinib or crizotinib, respectively, and the progression occurs in only a limited number of sites (oligoprogressive disease) it may be reasonable to consider LAT to the sites of progression and continuation of the TKI."


'/>"/>

Contact: Kristal Griffith
Kristal.Griffith@iaslc.org
720-325-2952
International Association for the Study of Lung Cancer
Source:Eurekalert

Page: 1

Related medicine news :

1. Study reveals insights that could aid in therapeutic use of mesenchymal stem cells
2. Alcoholic Drinks Add 100 Calories a Day to Average Adults Diet: Study
3. Cash cuts increase smoking death risk for worlds poor, study says
4. Study finds asthma is not linked to lower educational attainment
5. RSV study shows potential for vaccine strategies to protect babies
6. Lyme Rash Reappearance Probably Signals New Infection, Study Says
7. Study finds reformulated ER Oxycodone abuse rates are significantly lower than original ER Oxycodone
8. Month of Birth Might Help Determine MS Risk, Study Suggests
9. Study Reveals Gender Gap in Spotting Depression
10. Patients More Likely to Survive In-Hospital Cardiac Arrest Today: Study
11. Bright Light at Night Could Up Depression Risk, Mouse Study Suggests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... ... semi-final round of the 2017 Cupid's Cup Entrepreneurship Competition. Chaired by Under Armour ... in 2017. The entrepreneurs will showcase their businesses on February 6, 2017, at ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... today that its annual Solutions Series of webinars will start January 31 with ... discussing a number of current health and benefits topics, including employee engagement, pricing ...
(Date:1/24/2017)... ... January 24, 2017 , ... His message has been heard by more than ... End Distracted Driving , Joel Feldman, has reached his biggest national audience yet: the ... of the top newspapers in circulation in the country, and he hopes it will ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... Center ... 21st century leadership, has named Hector M. Chavez, Manager, Employee & Labor Relations at ... center - as its Hispanic Leader of the Month. City of Hope is committed ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... is the focus of a new report from the Frank Hawkins Kenan ... School. , Influential business leaders, academics and policy makers identified concrete solutions at ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... Aptuit, LLC, hat heute den ... Massachusetts General Hospital (MGH) unter Leitung von Dr. ... Identifizierung und Validierung neuartiger Targets in gramnegativen Bakterien.  Aptuit ... von Antibiotika bei der Behandlung schwerer Infektionen entgegenwirken können. ... ...
(Date:1/24/2017)... -- Laboratory Markets Limited has completed a comprehensive market ... both clinical and research laboratory settings. This study, which ... $6.8 billion and growing to $9.2 billion (CAGR of ... of mass spectrometry across more than 5,200 clinical and ... in the use of mass spectrometry in terms of ...
(Date:1/24/2017)... 2017 Global Market for Pharmaceutical ... A majority of medicines & drugs produced in ... (API), and such processes require alcoholic solvents such as ... of pharmaceutical solvents continues to be concentrated in the ... (APEJ) region as leading API suppliers and ...
Breaking Medicine Technology: